A call to action to advance patient‐focused and decentralized clinical trials-Reference-Cited by-同舟云学术

A call to action to advance patient‐focused and decentralized clinical trials

Published:2024-01-09 Issue: Volume: Page:
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Harvey R. Donald¹^ORCID,Miller Therica M.²^ORCID,Hurley Patricia A.³,Thota Ramya⁴^ORCID,Black Lora J.⁵^ORCID,Bruinooge Suanna S.³,Boehmer Leigh M.⁶,Fleury Mark E.⁷,Kamboj Jasmine⁸,Rizvi Mujahid A.⁹,Symington Banu E.¹⁰,Tap William D.¹¹,Waterhouse David M.¹²,Levit Laura A.³,Merrill Janette K.³,Prindiville Sheila A.¹³,Pollastro Teri¹⁴,Brewer Jamie R.¹⁵,Byatt Leslie P.¹⁶,Hamroun Leila¹⁷,Kim Edward S.¹⁸,Holland Nicole³,Nowakowski Grzegorz S.¹⁹

Affiliation:

1. Winship Cancer Institute of Emory University Atlanta Georgia USA

2. Icahn School of Medicine at Mount Sinai Tisch Cancer Institute New York New York USA

3. American Society of Clinical Oncology Alexandria Virginia USA

4. Intermountain Health Salt Lake City Utah USA

5. Sanford Health Sioux Falls South Dakota USA

6. Association of Community Cancer Centers Rockville Maryland USA

7. American Cancer Society Cancer Action Network Washington District of Columbia USA

8. Allina Health System River Falls Wisconsin USA

9. Hematology Oncology Associates Medford Oregon USA

10. Sweetwater Regional Cancer Center Rock Springs Wyoming USA

11. Memorial Sloan Kettering Cancer Center New York New York USA

12. Oncology Hematology Care, Inc. Cincinnati Ohio USA

13. National Cancer Institute Coordinating Center for Clinical Trials Bethesda Maryland USA

14. Metastatic Breast Cancer Alliance Mercer Island Washington USA

15. US Food and Drug Administration Rockville Maryland USA

16. New Mexico Cancer Care Alliance Albuquerque New Mexico USA

17. ChristianaCare OPACT Newark Delaware USA

18. City of Hope Duarte California USA

19. Mayo Clinic Rochester Minnesota USA

Abstract

This commentary is a call to action for a concerted commitment and effort to transform clinical trials and enable people with cancer to participate in clinical trials closer to home. Three key strategies are identified to address major barriers: confront challenges with the interpretation of US Food and Drug Administration Form 1572 requirements (Statement of Investigator); broaden acceptance of local laboratories and imaging centers; and invest in the creation of effective, sustainable partnerships between research centers and local providers.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference47 articles.

1. Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial Participation

2. Combating Structural Inequities — Diversity, Equity, and Inclusion in Clinical and Translational Research

3. The Ethical Imperative of Equity in Oncology: Lessons Learned From 2020 and a Path Forward

4. American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care

5. Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement